NovaDigm raises $14m for fungal, bacterial vaccines
This article was originally published in Scrip
NovaDigm Therapeutics raised $14m in Series B venture capital to finance the development of vaccines against fungal and bacterial infections, including an ongoing Phase Ib/IIa clinical trial for the NDV-3 vaccine to treat women with recurrent vulvovaginal candidiasis (RVVC), or vaginal yeast infections.
You may also be interested in...
Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.
Aimovig, Emgality and Ajovy have been on the market for more than a year, but are still far from blockbusters even though millions of patients are eligible for treatment – and at least one new competitor is coming.